Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)

Background The clinical course of alpha-1 antitrypsin deficiency (AATD) is very heterogeneous. It is estimated that 60% of individuals with severe AATD (Pi*ZZ) develop emphysema. The main objective of this study was to describe the outcomes of long-term lung function in individuals with AATD-associated emphysema after at least 8 years of follow-up. Materials and methods We performed a retrospective analysis of longitudinal follow-up data of AATD PiZZ patients from the Spanish registry (AATD Spanish Registry [REDAAT]). The main follow-up outcome was the annual rate of decline in forced expiratory volume in 1 second (FEV1) calculated using the FEV1 values at baseline and in the last post-bronchodilator spirometry available. Results One hundred and twenty-two AATD PiZZ patients were analyzed. The median follow-up was 11 years (interquartile range =9–14). The mean FEV1 decline was 28 mL/year (SD=54), with a median of 33 mL/year. Tobacco consumption (β=19.8, p<0.001), previous pneumonia (β=27.8, p=0.026) and higher baseline FEV1% (β=0.798, p=0.016) were independently related to a faster FEV1 decline. Conclusion In this large cohort with a long follow-up, we observed a very variable decline of FEV1. However, the mean FEV1 decline was similar to that observed in large cohorts of smoking-related COPD. Tobacco consumption, previous pneumonia and better lung function at baseline were related to a faster decline in FEV1. These results highlight the importance of early diagnosis and effective treatment.

[1]  F. Blasi,et al.  Neutrophil elastase in bronchiectasis , 2017, Respiratory Research.

[2]  M. Miravitlles,et al.  Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency , 2017, International journal of chronic obstructive pulmonary disease.

[3]  A. Dirksen,et al.  European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency , 2017, European Respiratory Journal.

[4]  A. Lindberg,et al.  Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits , 2017, European Respiratory Journal.

[5]  Jeffrey L. Curtis,et al.  Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease , 2016, American journal of respiratory and critical care medicine.

[6]  M. Miravitlles,et al.  Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency: Database Evaluation and Population Analysis. , 2017 .

[7]  R. Stockley,et al.  Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? , 2016, International journal of chronic obstructive pulmonary disease.

[8]  A. Kallio,et al.  Individual FEV1 Trajectories Can Be Identified from a COPD Cohort , 2016, COPD.

[9]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[10]  N. Schellack,et al.  Chronic obstructive pulmonary disease: an update , 2015 .

[11]  M. Miravitlles,et al.  Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals , 2015, COPD.

[12]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[13]  R. Stockley,et al.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach , 2013, Orphanet Journal of Rare Diseases.

[14]  P. Casán,et al.  Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). , 2013, Archivos de bronconeumologia.

[15]  Satoshi Konno,et al.  Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[16]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[17]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[18]  M. Miravitlles,et al.  Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry. , 2011, Archivos de bronconeumologia.

[19]  B. Stoel,et al.  Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry , 2010, Respiratory research.

[20]  A. Dirksen,et al.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[21]  R. Stockley,et al.  Rate of progression of lung function impairment in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[22]  R. Stockley,et al.  Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development , 2007, European Respiratory Journal.

[23]  D. Lomas,et al.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. , 2002, The Journal of clinical investigation.

[24]  M. Miravitlles,et al.  Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. , 1998, Respiratory medicine.

[25]  M. Schluchter,et al.  Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. , 1997, Chest.

[26]  D. Lomas,et al.  Alpha 1-antitrypsin deficiency. A conformational disease. , 1996, Chest.

[27]  N. Seersholm,et al.  Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. , 1995, American journal of respiratory and critical care medicine.

[28]  M. Miravitlles,et al.  [A report on the Spanish Registry of Patients with Alpha 1-Antitrypsin Deficiency. The Alpha 1-Antitrypsin Deficiency Study Group]. , 1995, Archivos de bronconeumologia.

[29]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[30]  J. Bloom,et al.  The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. , 1987, The New England journal of medicine.

[31]  P M Moodie,et al.  COHORT , 1971, The Medical journal of Australia.